Remedy is Awarded Key Formulation Patent by the USPTO
“Formulations and methods for lyophilization and lyophilates provided thereby” provides Remedy broad intellectual property protection.
New York, NY, USA - October 2, 2012 – Remedy Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. patent 8,277,845 titled "Formulations and methods for lyophilization and lyophilates provided thereby", which generally relates to the formulation of Remedy’s lead drug, RP-1127.
Remedy is the exclusive worldwide licensee of the patent portfolio related to NCCa- ATP channels developed by Dr. J. Marc Simard, Professor of Neurosurgery, Pathology and Physiology at the University of Maryland School of Medicine, and has its own wholly owned portfolio of patent applications related to formulation and dosing of RP-1127. This is the first Remedy owned patent to be issued.
“Enhancing and enforcing our licensed and wholly owned intellectual property portfolios is a strategic priority for our company,” said Sven Jacobson, Chief Executive Officer of Remedy. “The issuance of this new patent extends protection to our formulation and is an important addition to our current intellectual property portfolio.”
Remedy’s lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NCCa-ATP, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.
About Remedy Pharmaceuticals
Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.
For more information, email: firstname.lastname@example.org